vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
| VTVT Stock | USD 18.64 0.66 3.42% |
Slightly above 63% of VTv Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding vTv Therapeutics suggests that many traders are alarmed. VTv Therapeutics' investing sentiment can be driven by a variety of factors including economic data, VTv Therapeutics' earnings reports, geopolitical events, and overall market trends.
VTv |
HIGH POINT, N.C., March 01, 2024 -- vTv Therapeutics Inc. , a clinical stage biopharmaceutical company focused on the development of cadisegliatin as an adjunctive therapy to insulin for the treatment of type 1 diabetes , today announced that Company management will be presenting at the TD Cowen 44th Annual Healthcare Conference, being held March 4-6, 2024, in Boston, MA. The presentation is scheduled for Tuesday, March 5, 2024, at 950 AM ET. A liv
Read at finance.yahoo.com
 |
VTv Therapeutics Fundamental Analysis
We analyze VTv Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VTv Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VTv Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
VTv Therapeutics is currently under evaluation in target price category among its peers.
vTv Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with VTv Therapeutics stock to make a market-neutral strategy. Peer analysis of VTv Therapeutics could also be used in its relative valuation, which is a method of valuing VTv Therapeutics by comparing valuation metrics with similar companies.
Peers
VTv Therapeutics Related Equities
| ALLR | Allarity Therapeutics | 9.86 | ||||
| INM | InMed Pharmaceuticals | 2.12 | ||||
| ELEV | Elevation Oncology | 1.85 | ||||
| PHIO | Phio Pharmaceuticals | 1.36 | ||||
| GOVX | GeoVax Labs | 0.68 | ||||
| IMMX | Immix Biopharma | 0.61 | ||||
| EWTX | Edgewise Therapeutics | 0.28 | ||||
| ERAS | Erasca | 0.71 | ||||
| NBY | NovaBay Pharmaceuticals | 1.59 | ||||
| KRON | Kronos Bio | 2.00 | ||||
| VRAX | Virax Biolabs | 2.31 | ||||
| QNRX | Quoin Pharmaceuticals | 3.13 | ||||
| ZURA | Zura Bio | 3.76 | ||||
| CCCC | C4 Therapeutics | 5.02 | ||||
| GBIO | Generation Bio | 5.08 | ||||
| PYXS | Pyxis Oncology | 5.83 |
Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.